Dr. Tracy Kim Townsen did not arrive at psilocybin research from a lecture hall. She arrived from an operating room, after years of practicing surgery inside what she describes as a broken healthcare system. That personal reckoning eventually led her to co-found Meadow, which she calls the world’s first legal psychedelic medicine practice founded by a physician, and it put her at the center of one of the most quietly remarkable shifts in modern mental health science. The molecule at that center, psilocybin, is now among the most studied medicines for the brain and nervous system in clinical history, and the findings are forcing researchers to rethink what treatment-resistant depression, anxiety, PTSD, and addiction actually require.
What psilocybin actually does inside the brain
Psilocybin is the psychoactive compound found in more than 180 species of mushroom that grow on every continent except Antarctica. When ingested, the body converts it into an active metabolite called psilocin, which crosses the blood-brain barrier and binds primarily to a specific serotonin receptor subtype called the 5-HT2A receptor. That receptor is heavily concentrated in the brain’s default mode network, the system responsible for self-directed thought, overanalysis, and the mental loops that run through the past and future. Functional MRI studies have shown that psilocybin quiets this network significantly during a session.
Townsen draws a sharp distinction between what psilocybin does and what antidepressants do. Antidepressants, she explains, are designed to reduce emotional salience, which is why many patients report feeling emotionally flat while taking them. Psilocybin moves in the opposite direction: it heightens emotional salience while simultaneously quieting the ego-protective structures that normally make certain feelings feel unsafe to process. The result, for many participants, is a cathartic release and a reprocessing of memories that had been lodged in place for years.
The other window matters as much as the session itself. After a single dosing experience, the brain enters a period of increased neuroplasticity that can last several weeks. During that window, existing neural pathways built around old conditioning become more malleable, and new patterns of thought and behavior can be installed more deliberately, especially with the support of a therapist or psychedelic-informed guide.
What the clinical trials are actually showing
Psilocybin received FDA Breakthrough Therapy designation in both 2018 and 2019 for depression and treatment-resistant depression, driven by mounting trial data from institutions including Johns Hopkins, NYU, Imperial College London, and UCSF. The results from randomized, double-blind, placebo-controlled trials, the gold standard in clinical research, have been published in journals including the Lancet and the New England Journal of Medicine.
One Johns Hopkins study stands out. Just two doses of psilocybin produced relief from depression sustained out to one year in 75 percent of participants. More than half of that group entered complete remission, meaning they no longer met the clinical diagnostic criteria for depression at all. Townsen put it plainly: ‘We just don’t see results like that for any other intervention.’
Beyond depression, the research extends to anxiety, particularly existential anxiety in patients facing serious illness, as well as PTSD, addiction, and grief processing. Psilocybin does not work through the brain’s dopaminergic reward system, which means it carries no known addiction profile. A UK drug harm study ranked psilocybin mushrooms as the least harmful substance evaluated, both individually and in terms of collective societal harm.
The surgeon who used it herself
Townsen speaks from more than a clinical vantage point.
After describing the science, she reflects on what this medicine did for her personally during medical residency, a period she says psilocybin helped her not just survive but thrive through. The work since has changed, she says, and so have her relationships and her general way of moving through the world.
A single sentence from her account stays in the air: she describes the psilocybin experience as one in which ‘the volume of that inner narrator gets turned down, and then other aspects of ourselves get to be heard.’
For a former surgeon who spent years inside a system built around suppressing symptoms rather than resolving their source, that quiet was, apparently, the whole point.
